Vipin Kumar Chaturvedi
Co-Founder & Chief Scientific Officer GRI Bio, Inc.
Dr. Chaturvedi co-founded GRI in 2009 and, since its inception, has served as a member of its board of directors and as Chairman of its scientific advisory board. Dr. Chaturvedi served as GRI’s Chief Scientific Officer from 2009 to 2017 and reassumed the role in 2022. Dr. Chaturvedi has served as a Professor of Medicine, Laboratory of Immune Regulation at the University of California, San Diego since April 2015. In 2015, Dr. Chaturvedi co-founded Simomics, UK, a simulation software company and served as a non-executive director from 2015 to July 2022. Additionally, Dr. Chaturvedi has served on the board of directors of Vidur Discoveries, LLC, a consulting company, since 2009. Dr. Chaturvedi obtained his undergraduate degree in biology from the Kanpur University, India, his masters in biochemistry, molecular biology and immunology from the Institute of Medical Education & Research, India, and his Ph.D. in biochemistry from the Indian Institute of Science, India.
Seminars
- Unpacking the immunological drivers of fibrosis, including the role of invariant Natural Killer T (iNKT) cells in orchestrating epithelial injury, fibroblast activation, and chronic inflammatory signaling, and how targeting early immune regulators may shift disease trajectory beyond traditional antifibrotic approaches
- Designing a preclinical evaluation framework that moves beyond single models, integrating human-relevant systems (e.g., PCLS, ex vivo tissue), molecular readouts, and multi omic approaches to demonstrate true disease modification, not just attenuation of fibrosis
- Linking mechanism to translation through converging datasets, combining gene expression, circulating biomarkers, and immune phenotyping to build confidence in target engagement, biological relevance, and likelihood of clinical success prior to entering the clinic
